Market Tracker

09/29 5:16pm ET

Myriad Genetics Inc (NASDAQ:MYGN)

20.70
Delayed Data
As of 3:59pm ET
 -0.88 / -4.08%
Today’s Change
19.10
Today|||52-Week Range
46.24
-52.04%
Year-to-Date
3 Signs Invitae's Best Days Are Ahead
Sep 28 / MotleyFool.com - Paid Partner Content
Myriad Genetics Shouldn't Overlook This Tiny Competitor
Sep 17 / MotleyFool.com - Paid Partner Content
Myriad Genetics to Present myRisk Data at Seattle Conference
Sep 28 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close21.58
Today’s open21.51
Day’s range20.67 - 21.57
Volume1,746,323
Average volume (3 months)1,522,968
Market cap$1.5B
Dividend yield--
Data as of 3:59pm ET, 09/29/2016

Growth & Valuation

Earnings growth (last year)+58.33%
Earnings growth (this year)-35.68%
Earnings growth (next 5 years)+5.60%
Revenue growth (last year)+4.25%
P/E ratio12.1
Price/Sales2.98
Price/Book1.99

Competitors

 Today’s
change
Today’s
% change
AAAPAdvanced Accelerator...-0.09-0.23%
NEOGNeogen Corp-0.94-1.71%
VIVOMeridian Bioscience ...-0.42-2.13%
QDELQuidel Corp-1.02-4.66%
Data as of 3:59pm ET, 09/29/2016

Financials

Next reporting dateNovember 1, 2016
EPS forecast (this quarter)$0.26
Annual revenue (last year)$753.8M
Annual profit (last year)$125.3M
Net profit margin16.62%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts